Original Publication Date: 1 May, 2016
Publication / Source: Future Oncology
Authors: Ioannis Zerdes, Demosthenes E Ziogas, Efstathios G Lykoudis & Dimitrios H Roukos
In 2013, trastuzumab–emtasine conjugate (T-DM1) was approved by the US FDA for metastatic HER2-positive breast cancer. Now, a long-term expectation by patients and physicians becomes a reality for HER2-negative breast cancer. Palbociclib has recently received regulatory approval presenting a new therapeutic horizon for postmenopausal women with estrogen receptor-positive (ER+)/HER2-negative metastatic breast cancer.